Increased serum 1,25-dihydroxyvitamin D levels in gynecologic cancer patients with Post-Acute-Covid-Sequela (PASC)/Long COVID

por Bellone, Stefania, Siegel, Eric E., Santin, Alessandro D.
Publicado 2023

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)

por Santin, Alessandro D., Bellone, Stefania, Buza, Natalia, Schwartz, Peter E.
Publicado 2016

Improved survival of patients with hypermutation in uterine serous carcinoma

por Santin, Alessandro D., Bellone, Stefania, Centritto, Floriana, Schlessinger, Joseph, Lifton, Richard
Publicado 2015

Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment

por Han, Chanhee, Bellone, Stefania, Zammataro, Luca, Schwartz, Peter E., Santin, Alessandro D.
Publicado 2018

Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy

por McNamara, Blair, Bellone, Stefania, Demirkiran, Cem, Hartwich, Tobias Max Philipp, Santin, Alessandro D.
Publicado 2023

Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy

por McNamara, Blair, Bellone, Stefania, Demirkiran, Cem, Max Philipp Hartwich, Tobias, Santin, Alessandro D.
Publicado 2023

Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report

por Han, Chanhee, Bellone, Stefania, Schwartz, Peter E., Govindan, Serengulam V., Sharkey, Robert M., Goldenberg, David M., Santin, Alessandro D.
Publicado 2018

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma

por Pelligra, Silvia, Buza, Natalia, Hui, Pei, Bellone, Stefania, Zeybek, Burak, Ratner, Elena, Schwartz, Peter E., Scambia, Giovanni, Santin, Alessandro D.
Publicado 2020

Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers

por Bellone, Stefania, McNamara, Blair, Mutlu, Levent, Demirkiran, Cem, Hartwich, Tobias Max Philipp, Harold, Justin, Yang-Hartwich, Yang, Siegel, Eric R., Santin, Alessandro D.
Publicado 2023

Corrigendum to “Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutation...

por Santin, Alessandro D., Filiaci, Virginia, Bellone, Stefania, O'Cearbhaill, Roisin, Ratner, Elena S., Mathews, Cara A., Cantuaria, Guilherme, Gunderson, Camille C., Rutledge, Teresa, Buttin, Barbara M., Lankes, Heather A., Birrer, Michael J.
Publicado 2020

Human Ovarian Cancer Tumor Formation in Severe Combined Immunodeficient (SCID) Pigs

por Boettcher, Adeline N., Kiupel, Matti, Adur, Malavika K., Cocco, Emiliano, Santin, Alessandro D., Bellone, Stefania, Charley, Sara E., Blanco-Fernandez, Barbara, Risinger, John I., Ross, Jason W., Tuggle, Christopher K., Shapiro, Erik M.
Publicado 2019

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro

por Ferrari, Francesca, Bellone, Stefania, Black, Jonathan, Schwab, Carlton L., Lopez, Salvatore, Cocco, Emiliano, Bonazzoli, Elena, Predolini, Federica, Menderes, Gulden, Litkouhi, Babak, Ratner, Elena, Silasi, Dan-Arin, Azodi, Masoud, Schwartz, Peter E., Santin, Alessandro D.
Publicado 2015

Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGF(c )chimeric protein...

por Cocco, Emiliano, Varughese, Joyce, Buza, Natalia, Bellone, Stefania, Glasgow, Michelle, Bellone, Marta, Todeschini, Paola, Carrara, Luisa, Silasi, Dan-Arin, Azodi, Masoud, Schwartz, Peter E, Rutherford, Thomas J, Pecorelli, Sergio, Lockwood, Charles J, Santin, Alessandro D
Publicado 2011

T-DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo

por English, Diana P, Bellone, Stefania, Schwab, Carlton L, Bortolomai, Ileana, Bonazzoli, Elena, Cocco, Emiliano, Buza, Natalia, Hui, Pei, Lopez, Salvatore, Ratner, Elena, Silasi, Dan-Arin, Azodi, Masoud, Schwartz, Peter E, Rutherford, Thomas J, Santin, Alessandro D
Publicado 2014

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

por Black, Jonathan D, Lopez, Salvatore, Cocco, Emiliano, Bellone, Stefania, Altwerger, Gary, Schwab, Carlton L, English, Diana P, Bonazzoli, Elena, Predolini, Federica, Ferrari, Francesca, Ratner, Elena, Silasi, Dan-Arin, Azodi, Masoud, Schwartz, Peter E, Santin, Alessandro D
Publicado 2015

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

por Black, Jonathan D, Lopez, Salvatore, Cocco, Emiliano, Bellone, Stefania, Altwerger, Gary, Schwab, Carlton L, English, Diana P, Bonazzoli, Elena, Predolini, Federica, Ferrari, Francesca, Ratner, Elena, Silasi, Dan-Arin, Azodi, Masoud, Schwartz, Peter E, Santin, Alessandro D
Publicado 2015

Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncolo...

por Santin, Alessandro D., Filiaci, Virginia, Bellone, Stefania, Ratner, Elena S., Mathews, Cara A., Cantuaria, Guilherme, Gunderson, Camille C., Rutledge, Teresa, Buttin, Barbara M., Lankes, Heather A., Frumovitz, Michael, Khleif, Samir N., Huh, Warner K., Birrer, Michael J.
Publicado 2020

Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody

por Raji, Rhoda, Guzzo, Federica, Carrara, Luisa, Varughese, Joyce, Cocco, Emiliano, Bellone, Stefania, Betti, Marta, Todeschini, Paola, Gasparrini, Sara, Ratner, Elena, Silasi, Dan-Arin, Azodi, Masoud, Schwartz, Peter, Rutherford, Thomas J, Buza, Natalia, Pecorelli, Sergio, Santin, Alessandro D
Publicado 2011

Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer

por Cocco, Emiliano, Casagrande, Francesca, Bellone, Stefania, Richter, Christine E, Bellone, Marta, Todeschini, Paola, Holmberg, Jennie C, Fu, Han Hsuan, Montagna, Michele K, Mor, Gil, Schwartz, Peter E, Arin-Silasi, Dan, Azoudi, Masoud, Rutherford, Thomas J, Abu-Khalaf, Maysa, Pecorelli, Sergio, Santin, Alessandro D
Publicado 2010

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan

por Zeybek, Burak, Manzano, Aranzazu, Bianchi, Anna, Bonazzoli, Elena, Bellone, Stefania, Buza, Natalia, Hui, Pei, Lopez, Salvatore, Perrone, Emanuele, Manara, Paola, Zammataro, Luca, Altwerger, Gary, Han, Chanhee, Tymon-Rosario, Joan, Menderes, Gulden, Ratner, Elena, Silasi, Dan-Arin, Huang, Gloria S., Azodi, Masoud, Schwartz, Peter E., Santin, Alessandro
Publicado 2020